Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.
Merck, known as MSD outside of the United States, and Veeva Systems, a provider of cloud systems for the life sciences industry, announced a ten-year strategic partnership agreement on Nov. 1, 2022. Under the agreement, which builds on an existing 12-year partnership between the two companies, Merck will take a “Veeva-first approach” to new industry-specific software and data. Veeva will provide Merck with a strategic pricing approach and allow Merck input into their product roadmap.
“I am excited to see our partnership with Merck evolve to this strategic level,” said Peter Gassner, CEO, Veeva, in a company press release. “Our teams share a common passion for the industry and an understanding of strategic partnership. I look forward to seeing what we create together over the coming years.”
“Transforming our digital, data, and analytics capabilities is integral to enabling our global colleagues to deliver on our purpose of using the power of leading-edge science to save and improve lives around the world,” said Robert M. Davis, CEO and president, Merck, in the release. “Our strategic partnership with Veeva expands our capacity to leverage innovative technology and enhances our ability to deliver value to patients and all our stakeholders—this is key to how we measure success.”
Source: Veeva
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.